Goldline Pharmaceutical Limited (BOM:544759)

Market Cap	434.40M
Revenue (ttm)	280.56M +28.1%
Net Income	28.34M +1,270.5%
EPS	4.11 +1,096.5%
Shares Out	9.60M
PE Ratio	11.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,000
Open	42.01
Previous Close	42.96
Day's Range	42.01 - 46.89
52-Week Range	41.76 - 60.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 9, 2026

About Goldline Pharmaceutical

Goldline Pharmaceutical Limited engages in marketing pharmaceutical products under the brand name Goldline in India. Its products include goldline pharma, goldline cardinal, goldline aayushman, goldline inLife, and goldline wellness. The company serves physicians, orthopedics, ENT, chest physicians, general and specialty surgery, gastroenterology, neurology, urology, diabetologists, endocrinologists, cardiologists, general physicians, pediatricians, child specialists, neonatologists, intensivists, critical care consultants, and super specialty ...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2004
• Employees: 99
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544759

Financial Performance

In fiscal year 2025, Goldline Pharmaceutical's revenue was 280.56 million, an increase of 19.05% compared to the previous year's 235.66 million. Earnings were 28.34 million, an increase of 56.93%.